Helen joined Abingworth in April 2025 and works with our transatlantic investment team, with a particular focus on Clinical Co-Development, evaluating new investment opportunities and supporting existing investments.
Prior to Abingworth, Helen was a Senior Associate at Sagard Healthcare. She invested in approved and commercialized biopharmaceuticals, diagnostics, and medical devices that are protected by strong intellectual property through royalty monetization and private credit deals. Helen was responsible for all aspects of the investment process, including origination, due diligence, execution, and portfolio management. Before Sagard, Helen was an Associate on the Active Equities team at Canada Pension Plan Investment Board (“CPPIB”) and was responsible for making public equity investments within the healthcare sector. Helen started her career as an Analyst on the Life Science Technology and Venture Development team at MaRS Innovation.
Helen holds an Honors B.Sc. in Life Science and a Masters of Health Science, both from the University of Toronto. She is also a CFA charterholder.
